title: [Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice].
abstract: Only vitamin K antagonists could be applied as oral anticoagulants over the past six decades. Coumarols have narrow therapeutic range, and unpredictable anticoagulant effects are resulted by multiple drug interactions. Therefore, regular routine monitoring of the international normalized ratio is necessary. There are two groups of factor-specific anticoagulants: molecules with anti-FIIa (dabigatran) and anti-FXa (rivaroxaban, apixaban and edoxaban) effect. Author summarizes the most important clinical features of the new oral anticoagulants, their indications and the possibilities of laboratory controls. Bleedings are the most important side effects of anticoagulants. This review summarizes the current published evidences for new oral anticoagulants reversal (non-specific and specific) agents, especially in cases with severe acute bleedings or urgent surgery procedures. It reports on how to use inhibitors, the recommended doses and the most important clinical results. The review focuses on idarucizumab - already approved by the U.S. Food and Drug Administration and the European Medicines Agency - which has a key role as the first specific inhibitor of dabigatran.
authors.affiliation: Belgyógyászati Klinika, Thrombosis és Haemostasis Központ, Debreceni Egyetem, Klinikai Központ, Általános Orvostudományi Kar Debrecen, Nagyerdei krt. 98., 4032.
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Boda
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000553:Ambulatory Care; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects*; D000931:Antidotes / Q000627:therapeutic use*; D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects; D000069604:Dabigatran / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D015951:Factor Xa; D065427:Factor Xa Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D011720:Pyrazoles / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000037:antagonists & inhibitors; D011728:Pyridones / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins; D000069552:Rivaroxaban / Q000037:antagonists & inhibitors; D012720:Severity of Illness Index; D013514:Surgical Procedures, Operative; D013844:Thiazoles / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D000931:Antidotes; D000991:Antithrombins; D065427:Factor Xa Inhibitors; C580915:PRT064445; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D011994:Recombinant Proteins; D013844:Thiazoles; C522181:apixaban; C000594745:idarucizumab; D000069552:Rivaroxaban; D015951:Factor Xa; D000069604:Dabigatran; C552171:edoxaban
keywords: bleeding complications; idarucizumab; nem specifikus és specifikus antidótumok; new oral anticoagulants; non-specific and specific inhibitors; vérzéses szövődmények; új orális antikoagulánsok